The combination of cetuximab and anti-AurkA/B targeting in HNSCC cells ameliorates any polymorphism-related difference and increases the treatment efficiency, independent of the Aurora kinase genotype. This evidence concerns the gene AURKA and head and neck squamous cell carcinoma.